Literature DB >> 30246864

Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types.

Freja Laerke Sand1, Christian Munk1, Kirsten Frederiksen2, Jette Junge3, Thomas Iftner4, Christian Dehlendorff2, Susanne K Kjaer1,5.   

Abstract

Human papillomavirus (HPV) is essential in cervical carcinogenesis, however, less is known about the carcinogenic potential of individual HPV types. Our aim was to examine the risk of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) after persistence of 13 individual oncogenic HPV types. Liquid-based cervical samples (n = 40,399) collected in 2002-2005 were tested for HPV by hybrid capture 2 and genotyped with INNO-LiPAv2. Persistence was defined as having the same genotype twice 1-4.5 years apart. The absolute risk of CIN3+ was estimated by the Aalen-Johansen estimator and Cox proportional hazard regression was used to compare the rates of CIN3+ according to HPV type adjusting for age and time between HPV tests. Of 2,875 oncogenic HPV-positive women, 874 had persistence of one or more types and 761 persisted for one oncogenic HPV type only. Persistent HPV16 infection was associated with the highest risk of CIN3+, with an 8-year absolute risk of 55% (95% CI: 45%-66%), followed by HPV33 (33% (95% CI: 20%-50%)), HPV18 (32% (95% CI: 20%-48%)) and HPV31 (31% (95% CI: 21%-46%)). Other HPV types, including HPV52 and HPV45, were also associated with high risks. Persistent HPV56 had the lowest 8-year absolute risk of CIN3+ (3% (95% CI: 0.4%-20%)). In Cox analyses, a similar pattern remained after adjustment for age and time between tests. Our results add knowledge about the varying carcinogenic potential of individual persistent oncogenic HPV types, which may have implications for the clinical use of HPV testing.
© 2018 UICC.

Entities:  

Keywords:  cervical cancer; cervical neoplasia; human papillomavirus; prospective cohort study; type-specific persistence

Mesh:

Substances:

Year:  2019        PMID: 30246864     DOI: 10.1002/ijc.31883

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  [Prevention of HPV-induced diseases by prophylactic vaccination].

Authors:  Ulrike Wieland; Alexander Kreuter
Journal:  Hautarzt       Date:  2020-12-18       Impact factor: 0.751

2.  Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance.

Authors:  Ankur Chakravarthy; Ian Reddin; Stephen Henderson; Cindy Dong; Nerissa Kirkwood; Maxmilan Jeyakumar; Daniela Rothschild Rodriguez; Natalia Gonzalez Martinez; Jacqueline McDermott; Xiaoping Su; Nagayasau Egawa; Christina S Fjeldbo; Vilde Eide Skingen; Heidi Lyng; Mari Kyllesø Halle; Camilla Krakstad; Afschin Soleiman; Susanne Sprung; Matt Lechner; Peter J I Ellis; Mark Wass; Martin Michaelis; Heidi Fiegl; Helga Salvesen; Gareth J Thomas; John Doorbar; Kerry Chester; Andrew Feber; Tim R Fenton
Journal:  Nat Commun       Date:  2022-10-07       Impact factor: 17.694

3.  The Efficiency of Type-Specific High-Risk Human Papillomavirus Models in the Triage of Women with Atypical Squamous Cells of Undetermined Significance.

Authors:  Yangzhen Wang; Shanshan Gao; Yuxia Wang; Fuchun Chen; Hailong Deng; Yongfang Lu
Journal:  Cancer Manag Res       Date:  2020-07-01       Impact factor: 3.989

Review 4.  Vaginal microbiomes and ovarian cancer: a review.

Authors:  Jinyun Xu; Jing-Jie Peng; Wenqing Yang; Kun Fu; Yu Zhang
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

5.  Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age.

Authors:  Carole Fakhry; Tim Waterboer; William H Westra; Lisa M Rooper; Melina Windon; Tanya Troy; Wayne Koch; Christine G Gourin; Noemi Bender; Siddhartha Yavvari; Ana P Kiess; Brett A Miles; William R Ryan; Patrick K Ha; David W Eisele; Gypsyamber D'Souza
Journal:  Oral Oncol       Date:  2019-12-24       Impact factor: 5.337

6.  Long-term Persistence of Oral HPV Over 7 Years of Follow-up.

Authors:  Gypsyamber D'Souza; Gwendolyn Clemens; Howard D Strickler; Dorothy J Wiley; Tanya Troy; Linda Struijk; Maura Gillison; Carole Fakhry
Journal:  JNCI Cancer Spectr       Date:  2020-06-05

7.  Efficient combination of Human Papillomavirus Genotyping for the triage of women with Atypical Squamous Cells of Undetermined Significance in Chinese rural population: A population-based study.

Authors:  Wei Wang; Huina Zhang; Leqian Lin; Aimin Yang; Jing Yang; Weihong Zhao; Zhilian Wang; Lili Zhang; Xiaoqiang Su; Zhe Wang; Chen Wang; Haitao Zhang; Bo Feng; Dongyan Li; Huiqiang Liu; Xiaofen Niu; Jintao Wang; Jinghui Song; Li Li; Weiguo Lv; Chengquan Zhao; Min Hao
Journal:  J Cancer       Date:  2021-03-14       Impact factor: 4.207

8.  National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.

Authors:  Megan A Smith; Maddison Sherrah; Farhana Sultana; Philip E Castle; Marc Arbyn; Dorota Gertig; Michael Caruana; C David Wrede; Marion Saville; Karen Canfell
Journal:  BMJ       Date:  2022-03-30

9.  The impact of catch-up bivalent human papillomavirus vaccination on cervical screening outcomes: an observational study from the English HPV primary screening pilot.

Authors:  Francesca Pesola; Christopher Mathews; Matejka Rebolj; David Mesher; Kate Soldan; Henry Kitchener
Journal:  Br J Cancer       Date:  2022-03-26       Impact factor: 9.075

10.  Human Papillomavirus Same Genotype Persistence and Risk: A Systematic Review.

Authors:  Jesper Bonde; Fabio Bottari; Anna D Iacobone; Clementina E Cocuzza; Maria-Teresa Sandri; Fabrizio Bogliatto; Khalid S Khan; Ditte M Ejegod; Devin S Gary; Jeffrey C Andrews
Journal:  J Low Genit Tract Dis       Date:  2021-01-01       Impact factor: 3.842

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.